Dacetuzumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Dacetuzumab
Monoclonal antibody
TypeWhole antibody
SourceHumanized (from mouse)
TargetCD40
Clinical data
Other namesSGN-40
ATC code
  • none
Identifiers
CAS Number
  • 880486-59-9 ☒N
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6452H9964N1732O1998S42
Molar mass145,100 g/mol (for the peptide) g·mol−1
 ☒NcheckY (what is this?)  (verify)

Dacetuzumab (also known as SGN-40 or huS2C6) is a humanized monoclonal antibody[1] being developed for the treatment of CD40-positive cancers like non-Hodgkin's lymphoma[2] and hematological malignancies.[3]

This drug was developed by Seattle Genetics, Inc.

References[edit]

  1. ^ Statement On A Nonproprietary Name Adopted By The USAN Council - Dacetuzumab, American Medical Association.
  2. ^ Advani R, Forero-Torres A, Furman RR, Rosenblatt JD, Younes A, Ren H, et al. (September 2009). "Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma". Journal of Clinical Oncology. 27 (26): 4371–7. doi:10.1200/JCO.2008.21.3017. PMID 19636010.
  3. ^ Khubchandani S, Czuczman MS, Hernandez-Ilizaliturri FJ (June 2009). "Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies". Current Opinion in Investigational Drugs. 10 (6): 579–87. PMID 19513947.